Statistics on Biotechnology Use  
Results by sector of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Unidades: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1.056;551;183;323;
%Companies according to biotechnology used: Genetic code;36;46;22;26;
%Companies according to biotechnology used: Functional units;45;51;38;38;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;27;33;21;21;
%Companies according to biotechnology used: Bioprocesses;47;41;48;55;
%Companies according to biotechnology used: Sub-cellular organisms;8;12;8;4;
%Companies according to biotechnology used: Bio-computing;25;33;13;17;
%Companies according to biotechnology used: Nanobiotechnology;13;18;12;5;
%Companies according to biotechnology used: Other;15;16;16;13;
%Company by field(s) of ultimate application of biotechnology use: Human Health;49;65;38;27;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;20;25;19;13;
%Company by field(s) of ultimate application of biotechnology use: Food products;30;23;31;42;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;23;20;24;26;
%Company by field(s) of ultimate application of biotechnology use: Environment;13;11;25;11;
%Company by field(s) of ultimate application of biotechnology use: Industry;12;13;19;7;
Personnel in R&D in biotechnology (no. of persons);10.719;5.901;1.572;3.245;
Personnel in R&D in biotechnology (no. of persons): Researchers;6.131;3.640;912;1.579;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;4.588;2.261;661;1.667;
Personnel in R&D in biotechnology (no. of persons): women;6.040;3.443;844;1.753;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;3.411;2.087;511;812;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;2.629;1.356;333;941;
Personnel in R&D in biotechnology (FTE);7.751;4.659,2;980,5;2.111,1;
Personnel in R&D in biotechnology (FTE): Researchers;4.518,1;2.855,6;621;1.041,5;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;3.232,7;1.803,6;359,5;1.069,6;
Personnel in R&D in biotechnology (FTE): women;4.471,4;2.697,8;549,7;1.223,9;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2.562,7;1.637,8;360,6;564,3;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.908,7;1.060;189,1;659,6;
Internal expenditure on R&D (thousands of euros);679.558;446.123;82.011;151.424;
1) By nature of the expense: Current expenses;634.631;412.211;78.386;144.035;
1.1) Remuneration to researchers;228.857;153.206;31.881;43.769;
1.2) Remuneration to technicians and assistants;104.498;61.567;12.726;30.205;
1.3) Other current expenses;301.276;197.437;33.779;70.060;
2) By nature of the expense: Capital expenses;44.927;33.912;3.625;7.389;
2.1) Land and buildings;2.585;2.159;90;337;
2.2) Equipment and instruments;23.569;14.228;3.239;6.101;
2.3) Acquisition of specific R+D software;1.392;709;128;555;
2.4) Otros productos de propiedad intelectual específicos para I+D;17.381;16.817;168;396;
1) By origin of the funds: National funds;556.297;336.896;71.496;147.904;
1.1) Own funds;387.010;240.941;42.317;103.752;
1.2) From companies;86.025;41.093;17.175;27.757;
1.3) Public Administration funds;74.764;49.704;11.115;13.944;
1.4) From Universities;408;340;2;66;
1.5) From non profit private institutions;8.090;4.818;887;2.385;
1) By origin of the funds: Foreign funds;123.262;109.227;10.514;3.520;
2.1) From EU programmes;25.125;14.287;7.967;2.871;
2.2) Other foreign funds;98.137;94.940;2.547;649;
Purchase of R&D services in biotechnology (thousands of euros);147.558;104.940;19.473;23.146;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;76.875;54.648;12.216;10.011;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;70.683;50.292;7.256;13.135;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;49;59;45;32;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;14;11;20;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;16;13;25;17;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;13;12;21;10;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;18;20;24;12;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;18;21;19;11;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;17;16;21;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;40;39;33;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;51;56;52;44;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;18;17;22;18;
% Companies that have requested biotechnology patents;16;23;9;6;
Number of patents requested;746;539;142;65;
% Companies with income of an international origin related to biotechnological activities;23,3;33,8;11,6;12;
% Turnover representing income of an international origin related to biotechnological activities;1,2;14,5;0;0,7;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;60,4;66,6;74,8;24,7;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;39,6;33,4;25,3;75,3;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;80,9;78;70,6;98,2;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;17,8;21,3;0,3;1,3;
% Income of an international origin related with activities according to the classification: Operating source abroad;1,3;0,6;29;0,6;
% Income of an international origin related with activities according to the classification: Other;0,1;0,1;0;0;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute